Combination Treatment Options, Biomarkers, and Immune-related Adverse Event Occurrence and Management During the COVID-19 Pandemic
Track 1: Immuno-oncology in Advanced Melanoma

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.


TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.


LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Review the MOAs and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of melanoma
  • Summarize strategies for monitoring and managing irAEs associated with immunotherapies used alone or in combination across lines of therapy for the treatment of patients with melanoma
  • Describe the prognostic and predictive utility of melanoma biomarkers discovered through genomic testing, such as BRAFV600-mutations, that can inform patient-specific treatment decision making in the clinical practice setting
  • Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with melanoma during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
  • Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with melanoma and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination

ACCREDITATION AND DESIGNATION STATEMENTS

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 1.0 ANCC Contact Hour

Accreditation Statement
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

ONCC Statement
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.0 knowledge-based contact hour for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.


PROGRAM CHAIR & FACULTY PRESENTER

Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Co-Director, Melanoma Research Program
Professor of Medicine, NYU Grossman School of Medicine
New York, NY


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Weber has intellectual property or is a patent holder on a PD-1 biomarker patent with Biodesix, and a CTLA-4 biomarker patent with Moffitt Cancer Center. He has received consulting fees from BMS, GSK, Merck, Genentech, Amgen, Regeneron, Celldex, Incyte, Astra Zeneca, Pfizer, Protean, and Evax. He has ownership interest in Neximmune, Biond, and CytoMx; and has received royalties totaling 900 dollars from a patent held with the Moffitt Cancer Center.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, MPH, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for the enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: July 19, 2021

EXPIRATION DATE: July 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.


ENDURING ACTIVITY LEARNER NOTIFICATION

Med Learning Group
IC-ONC – Combination Treatment Options, Biomarkers and Immune-related Adverse Event Occurrence and Management During the COVID-19 Pandemic, Track 1: Advanced Melanoma
July 19, 2021 – July 19, 2022
Online

Acknowledgement of Financial Commercial Support
Bristol Myers Squibb

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-155-H04-P / JA4008163-9999-21-155-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives – After Attending This Program You Should Be Able To

  1. Review the MOAs and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of melanoma.
  2. Summarize strategies for monitoring and managing irAEs associated with immunotherapies used alone or in combination across lines of therapy for the treatment of patients with melanoma.
  3. Describe the prognostic and predictive utility of melanoma biomarkers discovered through genomic testing, such as BRAFV600-mutations, that can inform patient-specific treatment decision making in the clinical practice setting.
  4. Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with melanoma during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine.
  5. Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with melanoma and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

Name Relationship: Commercial Interest
Matthew Frese NA
Christina Gallo NA
Debra Gordon NA
Brianna Hanson NA
Scott McGee-Plys NA
Jessica McMullen NA
Jeffrey S. Weber Patent Holder: PD-1 biomarker – Biodesix, CTLA-4 biomarker – Moffitt Cancer Center; Consultant: BMS, GSK, Merck, Genentech, Amgen, Regeneron, Celldex, Incyte, Astra Zeneca, Pfizer, Protean, Evax; Allowed Ownership Interest: Neximmune, Biond, CytoMx
Lauren Welch NA

How to Get Your Certificate

  1. Go to http://mlg.cmecertificateonline.com
  2. Click on “IC-ONC Enduring – Track 1: Advanced Melanoma” link.
  3. Evaluate the meeting, click the provided link to open your credit certificate.
  4. Print/save all pages of your certificate for your records.

Questions?
Email Certificate@AmedcoEmail.com

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.